Outlook Therapeutics (NASDAQ:OTLK) released its quarterly earnings data on Thursday. The company reported ($0.10) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.31) by $0.21, Bloomberg Earnings reports. The company had revenue of $1.07 million during the quarter.
OTLK opened at $1.32 on Friday. Outlook Therapeutics has a 12 month low of $0.20 and a 12 month high of $1.37.
Separately, ValuEngine downgraded Outlook Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, January 29th.
WARNING: “Outlook Therapeutics (OTLK) Releases Quarterly Earnings Results, Beats Estimates By $0.21 EPS” was originally published by Modern Readers and is the property of of Modern Readers. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.modernreaders.com/news/2019/02/16/outlook-therapeutics-otlk-releases-quarterly-earnings-results-beats-estimates-by-0-21-eps.html.
About Outlook Therapeutics
Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.
Featured Article: Is the Dow Jones Industrial Average (DJIA) still relevant?
Receive News & Ratings for Outlook Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Outlook Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.